Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jun 1;84(2):162-172.
doi: 10.1097/QAI.0000000000002333.

Outcomes of Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe

Geoffrey Fatti  1   2 , Nicoletta Ngorima-Mabhena  3 , Eula Mothibi  1 , Trish Muzenda  1   4 , Regis Choto  5 , Tonderai Kasu  5 , Taurayi A Tafuma  6 , Nyika Mahachi  6 , Kudakwashe C Takarinda  5 , Tsitsi Apollo  5 , Owen Mugurungi  5 , Charles Chasela  7   8 , Risa M Hoffman  9 , Ashraf Grimwood  1
Affiliations
Randomized Controlled Trial

Outcomes of Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe

Geoffrey Fatti et al. J Acquir Immune Defic Syndr. .

Abstract

Introduction: Multimonth dispensing (MMD) of antiretroviral treatment (ART) aims to reduce patient-related barriers to access long-term treatment and improve health system efficiency. However, randomized evidence of its clinical effectiveness is lacking. We compared MMD within community ART refill groups (CARGs) vs. standard-of-care facility-based ART delivery in Zimbabwe.

Methods: A three-arm, cluster-randomized, pragmatic noninferiority trial was performed. Thirty health care facilities and associated CARGs were allocated to either ART collected three-monthly at facility (3MF, control); ART delivered three-monthly in CARGs (3MC); or ART delivered six-monthly in CARGs (6MC). Stable adults receiving ART ≥six months with baseline viral load (VL) <1000 copies/ml were eligible. Retention in ART care (primary outcome) and viral suppression (VS) 12 months after enrollment were compared, using regression models specified for clustering (ClinicalTrials.gov: NCT03238846).

Results: 4800 participants were recruited, 1919, 1335, and 1546 in arms 3MF, 3MC, and 6MC, respectively. For retention, the prespecified noninferiority limit (-3.25%, risk difference [RD]) was met for comparisons between all arms, 3MC (94.8%) vs. 3MF (93.0%), adjusted RD = 1.1% (95% CI: -0.5% to 2.8%); 6MC (95.5%) vs. 3MF: aRD = 1.2% (95% CI: -1.0% to 3.6%); and 6MC vs. 3MC: aRD = 0.1% (95% CI: -2.4% to 2.6%). VL completion at 12 months was 49%, 45%, and 8% in 3MF, 3MC, and 6MC, respectively. VS in 3MC (99.7%) was high and not different to 3MF (99.1%), relative risk = 1.0 (95% CI: 1.0-1.0). VS was marginally reduced in 6MC (92.9%) vs. 3MF, relative risk = 0.9 (95% CI: 0.9-1.0).

Conclusion: Retention in CARGs receiving three- and six-monthly MMD was noninferior versus standard-of-care facility-based ART delivery. VS in 3MC was high. VS in six-monthly CARGs requires further evaluation.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest are declared.

Figures

Figure 1.
Figure 1.
Trial flow diagram. CV, coefficient of variation of cluster size; IQR, interquartile range; CARGs, community ART refill groups; 3MF, participants received three-monthly dispensing of ART at the facility; 3MC, participants received three months’ supply of ART in CARGs; 6MC, participants received 6 months’ supply of ART in CARGs.
See this image and copyright information in PMC

References

    1. UNAIDS. UNAIDS Data 2019. 2019. https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data. Accessed November 7th, 2019.
    1. Grimsrud A, Bygrave H, Doherty M, et al. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J Int AIDS Soc 2016;19(1):21484. - PMC - PubMed
    1. Kates J, Wexler A, Lief E. Financing the response to HIV in low- and middle-income countries: international assistance from Donor Governments in 2015. 2016. http://www.kff.org/global-health-policy/report/financing-the-response-to.... Accessed April 15th, 2017.
    1. Maddison A, Schlech W. Will universal access to antiretroviral therapy ever be possible? The health care worker challenge. Can J Infect Dis Med Microbiol 2010;21(1):e64–e69. - PMC - PubMed
    1. Eshun-Wilson I, Mukumbwa-Mwenechanya M, Kim HY, et al. Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment. J Acquir Immune Defic Syndr 2019;81(5):540–546. - PMC - PubMed

Publication types

Substances

Associated data